

## SCHWEGMAN ■ LUNDBERG ■ WOESSNER ■ KLUTH

**Fax Transmission**

To:	Examiner Rebecca Cook	From:	Patti J. Jurkovich
Company:	USPTO	Date:	October 16, 2003
Fax #:	(703) 308-4242 703-746-5317	Re:	618.002US1

You should receive 4 pages, including this one  
If you do not receive all pages, please call (612) 349-9580.

**Message**

Dear Examiner Cook,

Attached are our proposed amendments for Serial No. 09/866458. I look forward to speaking with you about them today at 11 am your time, 10 am my time. I will initiate the telephone call.

FYI -- I can be reached at 612-349-9580 and my email is [pjurkovich@slwk.com](mailto:pjurkovich@slwk.com).

Very truly yours,  
Patti Jurkovich

This transmission contains information that is confidential and/or legally privileged. It is intended for use only by the person to whom it is directed. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us. If you do NOT receive all of the pages, please telephone us in the U.S.A. at (612) 339-0331 or FAX us at (612)339-3061.

*Patent Protection for High Technology*

Intellectual Property Attorneys

1600 TCF Tower, 121 South Eighth Street, Minneapolis, Minnesota 55402  
Telephone: 612-373-6900 Fax: 612-339-3061 Website: [www.slwk.com](http://www.slwk.com)

S/N 09/866458PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gary G. Meadows et al.

Examiner: Rebecca Cook

Serial No.: 09/866458

Group Art Unit: 1614

Filed: May 25, 2001

Docket: 618.002US1

Title: USE OF SEROTONIN AGENTS FOR ADJUNCT THERAPY IN THE  
TREATMENT OF CANCERDRAFT AMENDED CLAIM SET

- in vitro*
35. (New) A method of inhibiting the growth of a melanoma cell comprising contacting the melanoma cell with an effective amount of a serotonin agent. *reuptake*
36. (New) The method of claim 34, wherein the serotonin agent is a serotonin reuptake inhibitor.
37. (New) The method of claim 34, wherein the serotonin agent is a selective serotonin reuptake inhibitor (SSRI).
38. (New) The method of claim 35, wherein the serotonin agent is selected from fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and pharmaceutically acceptable salts thereof.
39. (New) The method of claim 38, wherein the serotonin agent is fluoxetine or a pharmaceutically acceptable salt thereof.
40. (New) The method of claim 35, wherein the melanoma cell is a pigmented cell.
41. (New) The method of claim 35, wherein the melanoma cell is a non-pigmented cell.
42. (New) A method for the treatment of melanoma in a mammal, which method comprises administering to said mammal an effective anti-melanoma amount of a serotonin agent. *in need thereof*

43. (New) The method of claim 42, wherein the serotonin agent is administered orally, subcutaneously, topically, or intravenously.

44. (New) The method of claim 42, wherein the serotonin agent is a serotonin reuptake inhibitor.

45. (New) The method of claim 42, wherein the serotonin agent is a selective serotonin reuptake inhibitor (SSRI).

46. (New) The method of claim 42, wherein the serotonin agent is selected from fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and pharmaceutically acceptable salts thereof.

47. (New) The method of claim 46, wherein the serotonin agent is fluoxetine or a pharmaceutically acceptable salt thereof.

48. (New) The method of claim 42, wherein the mammal is a human.

49. (New) A method of inhibiting metastasis, comprising administering an effective metastatic-inhibiting amount of a serotonin agent to a mammal. *in a mammal need then*

50. (New) The method of claim 49, wherein the serotonin agent is administered orally, subcutaneously, topically, or intravenously.

51. (New) The method of claim 49, wherein the serotonin agent is a serotonin reuptake inhibitor.

52. (New) The method of claim 49, wherein the serotonin agent is a selective serotonin reuptake inhibitor (SSRI).

53. (New) The method of claim 49, wherein the serotonin agent is selected from fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and pharmaceutically acceptable salts thereof.

54. (New) The method of claim 53, wherein the serotonin agent is fluoxetine or a pharmaceutically acceptable salt thereof.

55. (New) The method of claim 49, wherein the mammal is a human.